SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 533.40 |
| Enterprise Value ($M) | 938.05 |
| Book Value ($M) | 625.74 |
| Book Value / Share | 22.48 |
| Price / Book | 0.85 |
| NCAV ($M) | -298.90 |
| NCAV / Share | -10.74 |
| Price / NCAV | -1.78 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.23 |
| Return on Assets (ROA) | -0.16 |
| Return on Equity (ROE) | -0.29 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.00 |
| Current Ratio | 1.92 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 609.13 |
| Assets | 1,533.77 |
| Liabilities | 908.03 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 2,738.69 |
| Operating Income | -85.23 |
| Net Income | -266.41 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -53.41 |
| Cash from Investing | -78.64 |
| Cash from Financing | 131.47 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Ameriprise Financial Inc | 7.62 | 29.33 | |
| 13G/A | Vanguard Group Inc | 5.64 | 0.00 | |
| 13G/A | Dimensional Fund Advisors Lp | 6.60 | -18.92 | |
| 13G/A | BlackRock Inc. | 12.10 | 13.20 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 24,164 | 230,001 | 10.51 | |
| 9,754 | 140,896 | 6.92 | |
| 33,169 | 251,070 | 13.21 | |
| 22,258 | 178,866 | 12.44 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| QNCX – Quince Therapeutics, Inc. | QURE – uniQure N.V. |
| RARE – Ultragenyx Pharmaceutical Inc. | REGN – Regeneron Pharmaceuticals, Inc. |
| REPL – Replimune Group, Inc. |